Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
    Meeting Abstract

    Strickler, J.; Cercek, A.; Siena, S.; André, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A.; Hubbard, J.; Coveler, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Meeting Abstract

    Vogel, A.; Chan, S.; Furuse, J.; Tak, W.; Masi, G.; Varela, M.; Kim, J.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: Subanalysis of BEACON CRC
    Meeting Abstract

    Ng, K.; Ciardiello, F.; Van Cutsem, E.; Yaeger, R.; Yoshino, T.; Desai, J.; Wasan, H.; Alkuzweny, B.; Zhang, X.; Tabernero, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer
    Meeting Abstract

    Cytryn, S.; Lumish, M.; Paroder, V.; Philemond, S.; Lewis, J.; Lyashchenko, S.; Janjigian, Y.; Pandit-Taskar, N.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Novel frailty index predicts short-term outcomes after esophagectomy in elderly patients with esophageal cancer
    Meeting Abstract

    Boerner, T.; Tin, A.; Vickers, A.; Harrington, C.; Janjigian, Y.; Ilson, D.; Wu, A.; Bott, M.; Isbell, J.; Park, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Meeting Abstract

    Janjigian, Y.; Rha, S.; Oh, D.; Díez García, M.; van Laarhoven, H.; Chao, Y.; Di Bartolomeo, M.; Haj Mohammad, N.; Zhong, W.; Croydon, E.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
    Meeting Abstract

    Vienot, A.; Vernerey, D.; Bouard, A.; Klajer, E.; Asgarov, K.; Kim, S.; Tournigand, C.; Louvet, C.; André, T.; Rousseau, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset
    Meeting Abstract

    Garralda, E.; Hong, D.; Xu, R.; Deeken, J.; Italiano, A.; Liu, T.; Ferrandiz, A.; Patel, J.; Lee, D.; Chung, H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study (daNIS-3) of the antieTGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer
    Meeting Abstract

    Segal, N.; Rivera, F.; Tournigand, C.; Kasper, S.; Chen, Y.; Deshpande, P.; Messmann, R.; Kopetz, S.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in patients with HER2-high and HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Ku, G.; Piha-Paul, S.; Gupta, M.; Oh, D.; Kim, Y.; Lee, J.; Rha, S.; Kang, Y.; Diez García, M.; Fleitas Kanonnikoff, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save